Secukinumab/Adalimumab-Biosimilar

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Jun 4, 2019 → Sep 22, 2022

NCT ID

NCT03906136

About Secukinumab/Adalimumab-Biosimilar

Secukinumab/Adalimumab-Biosimilar is a phase 3 stage product being developed by Novartis for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03906136. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)

✅AdalimumabAbbVieApproved

✅Secukinumab 150 milligram [Cosentyx]NovartisApproved

✅Secukinumab + Placebo + SecukinumabNovartisApproved

✅etanercept + etanercept + placeboPfizerApproved

✅Tofacitinib 5 MGPfizerApproved

✅Certolizumab PegolUCBApproved

🔄Brodalumab + PlaceboKyowa KirinPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03906136	Phase 3	Completed	Jun 4, 2019	Sep 22, 2022	Axial Spondyloarthritis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31